{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:38:51Z","timestamp":1792975131342,"version":"4.5.0"},"reference-count":177,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2015,1,18]]},"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-language MEDLINE sources, we did not place a date-of-publication constraint. Hence, we have reviewed previous as well as most recent studies with the subject heading SLE in combination with each manifestation. Neutropenia can lead to morbidity and mortality from increased susceptibility to infection. Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. While related to disease activity, there is no specific therapy for lymphopenia. Severe lymphopenia may require the use of prophylactic therapy to prevent select opportunistic infections. Isolated idiopathic thrombocytopenic purpura maybe the first manifestation of SLE by months or even years. Some manifestations of lupus occur more frequently in association with low platelet count in these patients, for example, neuropsychiatric manifestation, haemolytic anaemia, the antiphospholipid syndrome and renal disease. Thrombocytopenia can be regarded as an important prognostic indicator of survival in patients with SLE. Medical, surgical and biological treatment modalities are reviewed for this manifestation. First-line therapy remains glucocorticoids. Through our review, we conclude glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely. Glucocorticoids are used as first-line therapy in patients with SLE with AIHA, but there is no conclusive evidence to guide second-line therapy. Rituximab is promising in refractory and non-responding AIHA. TTP is not recognised as a criteria for classification of SLE, but there is a considerable overlap between the presenting features of TTP and SLE, and a few patients with SLE have concurrent TTP. Myelofibrosis is an uncommon yet well-documented manifestation of SLE. We have compiled the cases that were reported in MEDLINE sources.<\/jats:p>","DOI":"10.1136\/lupus-2014-000078","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T21:33:17Z","timestamp":1425418397000},"page":"e000078","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":247,"title":["Haematological manifestations of lupus"],"prefix":"10.1136","volume":"2","author":[{"given":"Anum","family":"Fayyaz","sequence":"first","affiliation":[{"name":"Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"},{"name":"Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"},{"name":"Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Igoe","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"},{"name":"Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"},{"name":"Departments of Medicine and Pediatrics, Metro Health System, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biji T","family":"Kurien","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"},{"name":"Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"},{"name":"Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Danda","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"},{"name":"Department of Rheumatology, Christian Medical Center, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A","family":"James","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"},{"name":"Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"},{"name":"Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haraldine A","family":"Stafford","sequence":"additional","affiliation":[{"name":"Depertment of Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Hal","family":"Scofield","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"},{"name":"Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"},{"name":"Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,3,3]]},"reference":[{"key":"2025091515275564000_2.1.e000078.1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/art.1780150510","article-title":"An evaluation of the preliminary criteria for the diagnosis of systemic lupus erythematosus","volume":"15","author":"Lie","year":"1972","journal-title":"Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"2025091515275564000_2.1.e000078.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.11167"},{"key":"2025091515275564000_2.1.e000078.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2025091515275564000_2.1.e000078.5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830250211"},{"key":"2025091515275564000_2.1.e000078.6","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-195412000-00001"},{"key":"2025091515275564000_2.1.e000078.7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/art.1780350821","article-title":"Selective inhibition of granulopoiesis with severe neutropenia in systemic lupus erythematosus","volume":"35","author":"Arenas","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.8","doi-asserted-by":"publisher","DOI":"10.1053\/lc.1999.v133.a94931"},{"key":"2025091515275564000_2.1.e000078.9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.1780210503","article-title":"Autoimmune neutropenia in systemic lupus erythematosus","volume":"21","author":"Starkebaum","year":"1978","journal-title":"Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.1780260410","article-title":"Granulopoiesis in systemic lupus erythematosus","volume":"26","author":"Yamasaki","year":"1983","journal-title":"Arthritis Rheum"},{"issue":"(6 Pt 1)","key":"2025091515275564000_2.1.e000078.11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0002-9343(85)90220-7","article-title":"Complement-activating antineutrophil antibody in systemic lupus erythematosus","volume":"78","author":"Rustagi","year":"1985","journal-title":"Am J Med"},{"key":"2025091515275564000_2.1.e000078.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01195.x"},{"key":"2025091515275564000_2.1.e000078.13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1984.tb06078.x","article-title":"The severity of immune neutropenia correlates with the maturational specificity of antineutrophil antibodies","volume":"58","author":"Harmon","year":"1984","journal-title":"Br J Haematol"},{"key":"2025091515275564000_2.1.e000078.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780180405"},{"key":"2025091515275564000_2.1.e000078.15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.1780270623","article-title":"Severe neutropenia in systemic lupus erythematosus","volume":"27","author":"Gergely","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4274"},{"key":"2025091515275564000_2.1.e000078.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel016"},{"key":"2025091515275564000_2.1.e000078.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-006-0483-5"},{"key":"2025091515275564000_2.1.e000078.19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460224"},{"key":"2025091515275564000_2.1.e000078.20","first-page":"2153","article-title":"Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections","volume":"24","author":"Euler","year":"1997","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780210302"},{"key":"2025091515275564000_2.1.e000078.22","first-page":"269","article-title":"Deficiency of T cells in blood and tissues and severity of infections in systemic lupus erythematosus","volume":"67","author":"Bhuyan","year":"1978","journal-title":"Indian J Med Res"},{"key":"2025091515275564000_2.1.e000078.23","first-page":"228","article-title":"Study of lymphocyte subpopulations in normal humans and patients with systemic lupus erythematosus by fractionation of peripheral blood lymphocytes on a discontinuous Ficoll gradient","volume":"26","author":"Glinski","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"2025091515275564000_2.1.e000078.24","unstructured":"Laurence J , Wong JE , Nachman R . The cellular hematology of systemic lupus erythematosus. In: Lahita RG , ed. Systemic Lupus erythematosus. 2nd edn. New York: Churchhill Livingston, 1992:771\u2013806."},{"key":"2025091515275564000_2.1.e000078.25","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJM198506273122604","article-title":"Systemic lupus erythematosus with deficiency of the T4 epitope on T helper\/inducer cells","volume":"312","author":"Stohl","year":"1985","journal-title":"N Engl J Med"},{"key":"2025091515275564000_2.1.e000078.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.10.5970"},{"key":"2025091515275564000_2.1.e000078.27","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308099973"},{"key":"2025091515275564000_2.1.e000078.28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10067-011-1852-9","article-title":"Lymphopenia relating to T-lymphocyte apoptosis in systemic lupus erythematosus","volume":"30","author":"Chen","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2025091515275564000_2.1.e000078.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0781-6"},{"key":"2025091515275564000_2.1.e000078.30","doi-asserted-by":"publisher","DOI":"10.1177\/096120339300200112"},{"key":"2025091515275564000_2.1.e000078.31","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(92)90085-3"},{"key":"2025091515275564000_2.1.e000078.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.6.713"},{"key":"2025091515275564000_2.1.e000078.33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.3691261.x"},{"key":"2025091515275564000_2.1.e000078.34","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.4049\/jimmunol.152.7.3685","article-title":"Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus","volume":"152","author":"Emlen","year":"1994","journal-title":"J Immunol"},{"key":"2025091515275564000_2.1.e000078.35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2249.1995.tb05540.x","article-title":"Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia","volume":"99","author":"Amasaki","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2025091515275564000_2.1.e000078.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05848.x"},{"key":"2025091515275564000_2.1.e000078.37","first-page":"605","article-title":"Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus","volume":"80","author":"Nossent","year":"1991","journal-title":"Q J Med"},{"key":"2025091515275564000_2.1.e000078.38","first-page":"1191","article-title":"Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia","volume":"19","author":"Porges","year":"1992","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.39","unstructured":"Ginzler EM . Infections in systemic lupus erythematosus. In: Hahn BH . ed. DUBOIS's Lupus Erythematosus. 5th edn. Maryland: Williams & Wilkins, 1997:903\u201314."},{"key":"2025091515275564000_2.1.e000078.40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000207070","article-title":"Haematological aspects of systemic lupus erythematosus: a reappraisal using automated methods","volume":"67","author":"Isenberg","year":"1982","journal-title":"Acta Haematol"},{"key":"2025091515275564000_2.1.e000078.41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1316"},{"key":"2025091515275564000_2.1.e000078.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831"},{"key":"2025091515275564000_2.1.e000078.43","doi-asserted-by":"crossref","unstructured":"Kapouzas GA . Hematological and Lymphoid Abnomalities in SLE. In: Wallace DJ , Hahn BH , eds. DUBOIS\u2019 Lupus erythmatosus and Related Syndomes. 8th edn. Philadelphia: Elsevier, 2013:426\u201337.","DOI":"10.1016\/B978-1-4377-1893-5.00034-0"},{"key":"2025091515275564000_2.1.e000078.44","first-page":"482","article-title":"Platelet antibody binding in systemic lupus erythematosus","volume":"14","author":"Howe","year":"1987","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.45","first-page":"1067","article-title":"Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus","volume":"21","author":"Drenkard","year":"1994","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1600-0609.1986.tb02300.x","article-title":"Clinical significance of surface and internal pools of platelet-associated immunoglobulins in immune thrombocytopenia","volume":"37","author":"Fabris","year":"1986","journal-title":"Scand J Haematol"},{"key":"2025091515275564000_2.1.e000078.47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215368"},{"key":"2025091515275564000_2.1.e000078.48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08919.x"},{"key":"2025091515275564000_2.1.e000078.49","doi-asserted-by":"publisher","DOI":"10.1007\/BF02737640"},{"key":"2025091515275564000_2.1.e000078.50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1600-0609.1994.tb00195.x","article-title":"Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia","volume":"53","author":"Fabris","year":"1994","journal-title":"Eur J Haematol"},{"key":"2025091515275564000_2.1.e000078.51","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(90)90128-D"},{"key":"2025091515275564000_2.1.e000078.52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/clinchem\/47.6.1008","article-title":"Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications","volume":"47","author":"Nojima","year":"2001","journal-title":"Clin Chem"},{"key":"2025091515275564000_2.1.e000078.53","first-page":"632","article-title":"Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome","volume":"85","author":"Munoz-Rodriguez","year":"2000","journal-title":"Haematologica"},{"key":"2025091515275564000_2.1.e000078.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80249-6"},{"key":"2025091515275564000_2.1.e000078.55","first-page":"143","article-title":"Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients","volume":"15","author":"Lopez-Soto","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"2025091515275564000_2.1.e000078.56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1445-5994.1993.tb01809.x","article-title":"Clinical analysis of 125 patients with the lupus anticoagulant","volume":"23","author":"Morgan","year":"1993","journal-title":"Aust N Z J Med"},{"key":"2025091515275564000_2.1.e000078.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1003"},{"key":"2025091515275564000_2.1.e000078.58","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-682"},{"key":"2025091515275564000_2.1.e000078.59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0049-3848(90)90173-A","article-title":"A new platelet function test","volume":"58","author":"Ryan","year":"1990","journal-title":"Thromb Res"},{"key":"2025091515275564000_2.1.e000078.60","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363887"},{"key":"2025091515275564000_2.1.e000078.61","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/art.38672","article-title":"Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults","volume":"66","author":"Kumakura","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091515275564000_2.1.e000078.62","doi-asserted-by":"publisher","DOI":"10.1002\/art.10519"},{"key":"2025091515275564000_2.1.e000078.63","doi-asserted-by":"crossref","first-page":"130265","DOI":"10.1155\/2010\/130265","article-title":"Monocyte chemoattractant protein-1-2518 A\/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE","volume":"2010","author":"Piotrowski","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"2025091515275564000_2.1.e000078.64","first-page":"867","article-title":"Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus","volume":"24","author":"Mestanza-Peralta","year":"1997","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.65","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780261002"},{"key":"2025091515275564000_2.1.e000078.66","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197607000-00004"},{"key":"2025091515275564000_2.1.e000078.67","first-page":"351","article-title":"Hemolytic anemia and thrombocytopenic purpura: two related subsets of systemic lupus erythematosus","volume":"4","author":"Alger","year":"1977","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.4.399"},{"key":"2025091515275564000_2.1.e000078.69","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380218"},{"key":"2025091515275564000_2.1.e000078.70","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330105"},{"key":"2025091515275564000_2.1.e000078.71","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(91)90057-7"},{"key":"2025091515275564000_2.1.e000078.72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-0172(94)90094-9","article-title":"Survival of Chilean patients with systemic lupus erythematosus","volume":"24","author":"Massardo","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.73","doi-asserted-by":"publisher","DOI":"10.1136\/ard.48.6.447"},{"key":"2025091515275564000_2.1.e000078.74","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases","volume":"29","author":"Arnal","year":"2002","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.75","doi-asserted-by":"publisher","DOI":"10.1136\/ard.39.4.377"},{"key":"2025091515275564000_2.1.e000078.76","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360120123022"},{"key":"2025091515275564000_2.1.e000078.77","first-page":"682","article-title":"Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement","volume":"10","author":"Agnello","year":"1983","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.10.1095"},{"key":"2025091515275564000_2.1.e000078.79","doi-asserted-by":"crossref","first-page":"703","DOI":"10.7326\/0003-4819-108-5-703","article-title":"Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus","volume":"108","author":"West","year":"1988","journal-title":"Ann Intern Med"},{"key":"2025091515275564000_2.1.e000078.80","first-page":"1867","article-title":"Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans\u2019 syndrome","volume":"22","author":"Cervera","year":"1995","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.81","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6643.266"},{"key":"2025091515275564000_2.1.e000078.82","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1002\/art.38872","article-title":"Antibody-secreting cell specificity in labial salivary glands reflects clinical presentation and serology in sjogren's syndrome patients","volume":"66","author":"Maier-Moore","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091515275564000_2.1.e000078.83","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.10.1149"},{"key":"2025091515275564000_2.1.e000078.84","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409103065"},{"key":"2025091515275564000_2.1.e000078.85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/1096-8652(200009)65:1<85::AID-AJH17>3.0.CO;2-9","article-title":"Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia","volume":"65","author":"Chandramouli","year":"2000","journal-title":"Am J Hematol"},{"key":"2025091515275564000_2.1.e000078.86","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJM197408222910802","article-title":"Vincristine therapy of idiopathic and secondary thrombocytopenias","volume":"291","author":"Ahn","year":"1974","journal-title":"N Engl J Med"},{"key":"2025091515275564000_2.1.e000078.87","doi-asserted-by":"publisher","DOI":"10.1191\/096120301672970034"},{"key":"2025091515275564000_2.1.e000078.88","first-page":"352","article-title":"Extremely low dose treatment of cyclosporine for autoimmune diseases","volume":"16","author":"Sekigawa","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"2025091515275564000_2.1.e000078.89","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.7.669"},{"key":"2025091515275564000_2.1.e000078.90","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360516"},{"key":"2025091515275564000_2.1.e000078.91","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-674"},{"key":"2025091515275564000_2.1.e000078.92","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2013.28.3.472"},{"key":"2025091515275564000_2.1.e000078.93","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310384122"},{"key":"2025091515275564000_2.1.e000078.94","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.5.883"},{"key":"2025091515275564000_2.1.e000078.95","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq269"},{"key":"2025091515275564000_2.1.e000078.96","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309358599"},{"key":"2025091515275564000_2.1.e000078.97","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309351541"},{"key":"2025091515275564000_2.1.e000078.98","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker176"},{"key":"2025091515275564000_2.1.e000078.99","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311404913"},{"key":"2025091515275564000_2.1.e000078.100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036698"},{"key":"2025091515275564000_2.1.e000078.101","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2361"},{"key":"2025091515275564000_2.1.e000078.102","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<170::AID-ANR22>3.0.CO;2-T"},{"key":"2025091515275564000_2.1.e000078.103","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(88)80097-7"},{"key":"2025091515275564000_2.1.e000078.104","first-page":"366","article-title":"Splenectomy in systemic lupus erythematosis","volume":"52","author":"Gruenberg","year":"1986","journal-title":"Am Surg"},{"key":"2025091515275564000_2.1.e000078.105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.7326\/0003-4819-105-6-971_3","article-title":"Splenectomy and the thrombocytopenia of systemic lupus erythematosus","volume":"105","author":"Jacobs","year":"1986","journal-title":"Ann Intern Med"},{"key":"2025091515275564000_2.1.e000078.106","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-102-3-325"},{"key":"2025091515275564000_2.1.e000078.107","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1979.03630440039014"},{"key":"2025091515275564000_2.1.e000078.108","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(98)80024-3"},{"key":"2025091515275564000_2.1.e000078.109","first-page":"1","article-title":"Splenectomy has a limited role in the management of lupus with thrombocytopenia","volume":"29","author":"Alarcon-Segovia","year":"2002","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.110","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/00007611-198210000-00035","article-title":"Plasmapheresis in the treatment of resistant thrombocytopenia in systemic lupus erythematosus","volume":"75","author":"Wall","year":"1982","journal-title":"South Med J"},{"key":"2025091515275564000_2.1.e000078.111","first-page":"704","article-title":"Apheresis: clinical response to patients unresponsive to conventional therapy","volume":"31","author":"Sakamoto","year":"1985","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"2025091515275564000_2.1.e000078.112","first-page":"2058","article-title":"The role of anticardiolipin autoantibodies in the pathogenesis of autoimmune hemolytic anemia in systemic lupus erythematosus","volume":"20","author":"Sthoeger","year":"1993","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.113","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.1780300404","article-title":"Anticardiolipin antibodies in patients with systemic lupus erythematosus","volume":"30","author":"Sturfelt","year":"1987","journal-title":"Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.114","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600806"},{"key":"2025091515275564000_2.1.e000078.115","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230750"},{"key":"2025091515275564000_2.1.e000078.116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.15.5734"},{"key":"2025091515275564000_2.1.e000078.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.09.008"},{"key":"2025091515275564000_2.1.e000078.118","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jbspin.2011.07.004","article-title":"Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome","volume":"79","author":"Costallat","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2025091515275564000_2.1.e000078.119","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2292oa"},{"key":"2025091515275564000_2.1.e000078.120","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308098360"},{"key":"2025091515275564000_2.1.e000078.121","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken071"},{"key":"2025091515275564000_2.1.e000078.122","first-page":"65","article-title":"Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002\u20132004)","volume":"24","author":"Scheinberg","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"2025091515275564000_2.1.e000078.123","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschkowitz","year":"1924","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091515275564000_2.1.e000078.124","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.V2.6.542.542","article-title":"Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses","volume":"2","author":"Singer","year":"1947","journal-title":"Blood"},{"key":"2025091515275564000_2.1.e000078.125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine"},{"key":"2025091515275564000_2.1.e000078.126","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e318046583f"},{"key":"2025091515275564000_2.1.e000078.127","first-page":"260","article-title":"Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects","volume":"84","author":"Porta","year":"1999","journal-title":"Haematologica"},{"key":"2025091515275564000_2.1.e000078.128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392202"},{"key":"2025091515275564000_2.1.e000078.129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392203"},{"key":"2025091515275564000_2.1.e000078.130","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230411"},{"key":"2025091515275564000_2.1.e000078.131","first-page":"1469","article-title":"Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era","volume":"19","author":"Stricker","year":"1992","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.132","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318133a476"},{"key":"2025091515275564000_2.1.e000078.133","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2346::AID-ANR13>3.0.CO;2-X"},{"key":"2025091515275564000_2.1.e000078.134","doi-asserted-by":"publisher","DOI":"10.1080\/030097401753180417"},{"key":"2025091515275564000_2.1.e000078.135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MAJ.0b013e3181b0c872","article-title":"Clinical-pathological features and prognosis of thrombotic thrombocytopenic purpura in patients with lupus nephritis","volume":"338","author":"Zheng","year":"2009","journal-title":"Am J Med Sci"},{"key":"2025091515275564000_2.1.e000078.136","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken510"},{"key":"2025091515275564000_2.1.e000078.137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3810\/hp.1999.07.154","article-title":"Thrombotic thrombocytopenic purpura today","volume":"34","author":"Moake","year":"1999","journal-title":"Hospital practice (1995)"},{"key":"2025091515275564000_2.1.e000078.138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604"},{"key":"2025091515275564000_2.1.e000078.139","first-page":"37","article-title":"Coexistence of systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report","volume":"105","author":"Kafle","year":"2012","journal-title":"Tenn Med"},{"key":"2025091515275564000_2.1.e000078.140","first-page":"467","article-title":"Systemic lupus erythematosus presenting with pancytopenia due to bone marrow myelofibrosis in a 22-year-old male","volume":"2","author":"Aziz","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025091515275564000_2.1.e000078.141","first-page":"11","article-title":"[Cytology and histology of the human bone marrow]","volume":"4","author":"Burkhardt","year":"1968","journal-title":"Hamatologie und Bluttransfusion"},{"key":"2025091515275564000_2.1.e000078.142","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.36.11.1219"},{"key":"2025091515275564000_2.1.e000078.143","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.22.4.433"},{"key":"2025091515275564000_2.1.e000078.144","first-page":"825","article-title":"Bone marrow abnormalities in systemic lupus erythematosus with peripheral cytopenia","volume":"30","author":"Wanitpongpun","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025091515275564000_2.1.e000078.145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/00313029109061430","article-title":"Bone marrow findings in lupus patients with pancytopenia","volume":"23","author":"Feng","year":"1991","journal-title":"Pathology"},{"key":"2025091515275564000_2.1.e000078.146","doi-asserted-by":"publisher","DOI":"10.1007\/BF01451051"},{"key":"2025091515275564000_2.1.e000078.147","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600412"},{"key":"2025091515275564000_2.1.e000078.148","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.529"},{"key":"2025091515275564000_2.1.e000078.149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"2025091515275564000_2.1.e000078.150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"2025091515275564000_2.1.e000078.151","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092155"},{"key":"2025091515275564000_2.1.e000078.152","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133256"},{"key":"2025091515275564000_2.1.e000078.153","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket284"},{"key":"2025091515275564000_2.1.e000078.154","first-page":"802581","article-title":"Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus","volume":"2011","author":"Trivedi","year":"2011","journal-title":"Journal of biomedicine & biotechnology"},{"key":"2025091515275564000_2.1.e000078.155","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1002\/art.22799","article-title":"A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus","volume":"56","author":"Amengual","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2025091515275564000_2.1.e000078.156","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.gene.6364259","article-title":"Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia","volume":"6","author":"Nolsoe","year":"2005","journal-title":"Genes Immun"},{"key":"2025091515275564000_2.1.e000078.157","doi-asserted-by":"publisher","DOI":"10.1002\/art.34361"},{"key":"2025091515275564000_2.1.e000078.158","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311405704"},{"key":"2025091515275564000_2.1.e000078.159","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/iji.12041","article-title":"The interleukin 6 receptor alpha gene polymorphisms are associated with clinical manifestations of systemic lupus erythematosus in Koreans","volume":"40","author":"Jeon","year":"2013","journal-title":"Int J Immunogenet"},{"key":"2025091515275564000_2.1.e000078.160","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309357437"},{"key":"2025091515275564000_2.1.e000078.161","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090243"},{"key":"2025091515275564000_2.1.e000078.162","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0569-9"},{"key":"2025091515275564000_2.1.e000078.163","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2086oa"},{"key":"2025091515275564000_2.1.e000078.164","first-page":"1207","article-title":"Myelofibrosis secondary to SLE and its reversal on steroid therapy","volume":"32","author":"Agarwal","year":"1995","journal-title":"Indian Pediatr"},{"key":"2025091515275564000_2.1.e000078.165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000205641","article-title":"Myelofibrosis and pancytopenia in systemic lupus erythematosus","volume":"80","author":"el Mouzan","year":"1988","journal-title":"Acta Haematol"},{"key":"2025091515275564000_2.1.e000078.166","first-page":"1303","article-title":"Systemic lupus erythematosus presenting with myelofibrosis","volume":"19","author":"Foley-Nolan","year":"1992","journal-title":"J Rheumatol"},{"key":"2025091515275564000_2.1.e000078.167","first-page":"773","article-title":"[A case of systemic lupus erythematosus presenting with myelofibrosis as a cause of pancytopenia]","volume":"34","author":"Fukuya","year":"1994","journal-title":"Ryumachi [Rheumatism]"},{"key":"2025091515275564000_2.1.e000078.168","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000204592","article-title":"Myelofibrosis and systemic lupus erythematosus: reversal of fibrosis with high-dose corticosteroid therapy","volume":"88","author":"Inoue","year":"1992","journal-title":"Acta Haematol"},{"key":"2025091515275564000_2.1.e000078.169","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90373-6"},{"key":"2025091515275564000_2.1.e000078.170","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009113399"},{"key":"2025091515275564000_2.1.e000078.171","first-page":"153","article-title":"Systemic lupus erythematosus presenting as myelofibrosis","volume":"29","author":"Konstantopoulos","year":"1998","journal-title":"Haematologia"},{"key":"2025091515275564000_2.1.e000078.172","doi-asserted-by":"publisher","DOI":"10.1007\/BF02030356"},{"key":"2025091515275564000_2.1.e000078.173","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.37.6.714-a"},{"key":"2025091515275564000_2.1.e000078.174","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005792-199405000-00003","article-title":"Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus","volume":"73","author":"Paquette","year":"1994","journal-title":"Medicine (Baltimore)"},{"key":"2025091515275564000_2.1.e000078.175","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2169\/internalmedicine.48.1957","article-title":"Multisystem failure due to three coexisting autoimmune diseases","volume":"48","author":"Pillai","year":"2009","journal-title":"Intern Med"},{"key":"2025091515275564000_2.1.e000078.176","doi-asserted-by":"publisher","DOI":"10.1080\/00313029500169073"},{"key":"2025091515275564000_2.1.e000078.177","first-page":"522","article-title":"Myelofibrosis secondary to SLE and its reversal on steroid therapy","volume":"33","author":"Raut","year":"1996","journal-title":"Indian Pediatr"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2014-000078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:28:12Z","timestamp":1757975292000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2014-000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,3,3]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1136\/lupus-2014-000078"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2014-000078","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}